# NFKBIE

Source: https://onco.cc/targets/nfkbie/  
OnCo record `nfkbie` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.

## Summary

Sequesters NF-kappa-B transcription factor complexes in the cytoplasm, thereby inhibiting their activity. Sequestered complexes include NFKB1-RELA (p50-p65) and NFKB1-REL (p50-c-Rel) complexes. Limits B-cell activation in response to pathogens, and also plays an important role in B-cell development.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.72, genetic association 0.00, somatic mutation 0.81). IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Lung Adenocarcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: NFKB inhibitor epsilon; NF-kappa-B inhibitor epsilon
- Tags: cancer-genes-wave
- Symbol: NFKBIE
- Class: tumor-suppressor
- Biology: Sequesters NF-kappa-B transcription factor complexes in the cytoplasm, thereby inhibiting their activity. Sequestered complexes include NFKB1-RELA (p50-p65) and NFKB1-REL (p50-c-Rel) complexes. Limits B-cell activation in response to pathogens, and also plays an important role in B-cell development. Location: Cytoplasm (UniProt). Locus 6p21.1 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059); Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Diffuse large B-cell lymphoma: Open Targets association 0.53 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease; Mantle cell lymphoma: CIViC evidence names this disease; Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:7799: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7799
- UniProt O00221: https://www.uniprot.org/uniprotkb/O00221/entry
- NCBI Gene 4794: https://www.ncbi.nlm.nih.gov/gene/4794
- Ensembl ENSG00000146232: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146232

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nfkbie.json